✦ LIBER ✦

Cost–utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma

✍ Scribed by Nina Gulbrandsen; Finn Wisløff; Erik Nord; Stig Lenhoff; Martin Hjorth; Jan Westin; Nordic Myeloma Study Group

Book ID: 114423033
Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 101 KB
Volume: 66
Category: Article
ISSN: 0902-4441
DOI: 10.1034/j.1600-0609.2001.066005328.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of time to infusion of autologous

Effect of time to infusion of autologous stem cells (24 vs. 48 h) after high-dose melphalan in patients with multiple myeloma

✍ Giampaolo Talamo; Kevin L. Rakszawski; Witold B. Rybka; Nathan G. Dolloff; Jozef 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

Phase I–II evaluation of rapid sequence

Phase I–II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma

✍ Weaver, C H; Zhen, B; Schwartzberg, L S; Leff, R; Magee, M; Geier, L; Deaton, K; 📂 Article 📅 1998 🏛 Nature Publishing Group 🌐 English ⚖ 61 KB

Veno-Occlusive Disease of the Liver afte

Veno-Occlusive Disease of the Liver after High-Dose Cytoreductive Therapy with Busulfan and Melphalan for Autologous Blood Stem Cell Transplantation in Multiple Myeloma Patients

✍ Enric Carreras; Laura Rosiñol; Maria José Terol; Adrián Alegre; Felipe de Arriba 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 145 KB

High-dose melphalan (200 mg/m2) supporte

High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (65 years) myeloma patients: comparison with younger patients treated on the same protocol

✍ Jantunen, E; Kuittinen, T; Penttilä, K; Lehtonen, P; Mahlamäki, E; Nousiainen, T 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 135 KB

Aprepitant for the control of delayed na

Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study

✍ Bechtel, Thomas; McBride, Ali; Crawford, Brooke; Bullington, Susan; Hofmeister, 📂 Article 📅 2014 🏛 Springer-Verlag 🌐 English ⚖ 248 KB

Cyclophosphamide plus dexamethasone is a

Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma : Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone

✍ Ulf-Henrik Mellqvist; Stig Lenhoff; Hans E. Johnsen; Martin Hjorth; Erik Holmber 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 2 views

## Abstract ## BACKGROUND Today, intensive therapy that includes high‐dose melphalan with autologous stem cell transplantation (ASCT) is considered standard therapy in younger patients with newly diagnosed myeloma. When the current trial was initiated, combined vincristine, doxorubicin, and dexame